Efficacy of rifaximine in intestinal bacterial overgrowth syndrome in patients after cholecystectomy


如何引用文章

全文:

详细

Aim. To define frequency of onset of small intestinal bacterial overgrowth syndrome (SIBOGS) in patients with postcholecystomy syndrome (PCS); to substantiate necessity of microflora correction and assess efficacy of rifaximine in the doses 800 and 1200 mg/day.
Material and methods. A breath hydrogen test (BHT) was made in 82 PCS patients. Rifaximine was given to 40 SIBOGS patients: 20 of them received the drug in a dose 800 mg/day and 20 - in a dose 1200 mg/day for 7 days. The efficacy was estimated by attenuation of the clinical symptoms and parameters of BHT.
Results. SIBOGS was detected in 73% of PCS patients. This was an indication for antibacterial treatment. Rifaximine in a dose 800 mg/day failed to attenuate pain and to eliminate dyspeptic syndromes in some patients, BHT in them was not normal. Administration of rifaximine in a dose 1200 mg/day normalized BHT in 90% patients and eliminated clinical symptoms in most of the patients. Conclusion. Rifaximine in a dose 1200 mg/day vs 800 mg/day in PCS patients with SIBOGS is more effective as it eliminates clinical symptoms and normalizes BHT.

作者简介

Tat'yana Mechetina

Email: tatyana22_82@mail.ru

Anatoliy Il'chenko

T Mechetina

Central Research Institute of Gastroenterology, Moscow

Central Research Institute of Gastroenterology, Moscow

A Ilchenko

Central Research Institute of Gastroenterology, Moscow

Central Research Institute of Gastroenterology, Moscow

参考

  1. Lakshmi C. P., Ghoshal U. C., Kumar S. et al. Frequency and factors associated with small intestinal bacterial overgrowth in patients with cirrhosis of the liiver and extra hepatic portal venous obstruction. Dig. Dis. Sci. 2009; 1: 10.
  2. Парфенов А. И. Энтерология. М.: МИА; 2009.
  3. Stotzer P. O., Kilander A. F. Comparison of the 1-gram (14) C-D-xylose breath test and the 50-gram hydrogen glucose breath test for diagnosis of small intestinal bacterial overgrowth. Digestion. 2000; 61 (3): 165-171.
  4. Stotzer P. O., Brandberg A., Kilander A. F. Diagnosis of small intestinal bacterial overgrowth in clinical practis: a comparison of the culture of small bowel aspirate, duodenal biopsies and gastric aspirate. Hepatogastroenterology 1998; 45 (22): 1018-1022.
  5. Khoshini R., Dai S. C., Lezcano S. et al. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig. Dis. Sci. 2008; 53 (6): 1443-1454.
  6. Rana S. V., Bhardwaj S. B. Small intestinal bacterial overgrowth. Scand. J. Gastroenterol. 2008; 43 (9): 1030-1037.
  7. Gasbarrini A., Lauritano E. C., Gabrielli M. et al. Small intestinal bacterial overgrowth: diagnosis and treatment. Dig. Dis. 2007; 25 (3): 237-240.
  8. Ардатская М. Д., Минушкин О. Н., Дубинин А. В. Дисбактериоз кишечника: современные аспекты изучения проблемы, принципы диагностики и лечения (обзор). Тер. арх. 2001; 2: 67-72.
  9. Парфенов А. И., Ручкина И. Н., Осипов Г. А. Дисбактериоз кишечника: вопросы биологической терапии. Трудный пациент 2007; 5: 32-34.
  10. Григорьев П. Я., Яковенко Э. П. Нарушение нормального состава кишечного биоценоза и методы его коррекции. Рус. мед. журн. 2004; 6 (2): 84.
  11. Яковенко Э. П., Иванов А. Н., Казарина А. В. и др. Нарушение нормального состава кишечных бактерий: клиническое значение и вопросы терапии. Рус. мед. журн. 2008; 10 (2): 41-46.
  12. Esposito I., de Leone A., Di Gregorio G. et al. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. Wld J. Gastroenterol. 2007; 13 (45): 6016-6021.
  13. Шептулин А. А., Торрес Э. А. Современные возможности применения; рифаксимина в гастроэнтерологии. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2008; 18 (5): 17-22.
  14. Jiang Z.-D. et al. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob. Agents Chemother. 2000; 44 (8): 2205-2206.
  15. Gillis J. C., Brogden R. N. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995; 49 (3): 467-484.
  16. Gomi H. et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. Antimicrob. Agents Chemother. 2001; 45 (1): 212-216.
  17. Мечетина Т. А., Ильченко А. А. Эффективность рифаксимина при синдроме избыточного бактериального роста у больных после холецистэктомии. Экспер. и клин. гастроэнтерол. 2010; 4: 100-105.
  18. Mendoza Е., Crismatt C., Matos R. et al. Diagnosis of small intestinal bacterial overgrowth in children: the use of lactulose in the breath hydrogen test as a screening test. Biomedica. 2007; 27 (3): 325-332.
  19. Scarpellini E., Gabrielli M., Lauritano C. E. et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment. Pharmacol. Ther. 2007; 25 (7): 781-786.
  20. Lauritano E. C., Gabrielli M., Lupascu A. et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment. Pharmacol. Ther. 2005; 22 (1): 31- 35.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2011

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


##common.cookie##